Expected New Trends in Cardiology and Cardiovascular Medical Devices
Reported: Aviva Lev-Ari, PhD, RN
UPDATED on 11/22/2018 – Published Activity on http://pharmaceuticalintelligence.com
-
World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(c) Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
UPDATED on 11/22/2018 – External Sources
-
Latest Medical Devices, Equipment, & Drug Information in Cardiology
Search the latest Cardiology developments in medical devices, equipment and approved drugs. Find new FDA approved procedures, drugs and devices in the MDLinx Product Center.
https://www.mdlinx.com/cardiology/product-center/
-
5 New Implantable Cardiovascular Technologies to Watch
Recent device technology advances may offer new therapies for atrial fibrillation and heart failure
https://www.dicardiology.com/article/5-new-implantable-cardiovascular-technologies-watch
-
Advances and Trends in Vascular Closure Devices
Faster hemostasis saves nursing time, speeds patient ambulation
https://www.dicardiology.com/article/advances-and-trends-vascular-closure-devices
-
Drivers and Trends in Cardiovascular Device Development: Insights from Key Opinion Leaders
Medical Device Clinical Trials, Medical Device Design, Medical Device Manufacturing & Supply Chain, Medical Device Safety and Regulation
https://xtalks.com/webinars/cardiovascular-device-development-insights-from-key-opinion-leaders/
Cardiology Industry 2018
View Trends, Analysis and Statistics.
Reportlinker.com offers immediate download access to top market reports on the Cardiology Industry.
US Cardiology Industry 2018-2022
-
157 Reports
- Demographic, Demand, Company Financials…
-
844 Statistics
- Demographic, Environment, Market Size…
Global Cardiology Industry 2018-2022
-
11 Reports
- Demographic, Supply, Demand…
-
168 Statistics
- Market Size, Demand, Company…
European Cardiology Industry 2018-2022
-
6 Reports
- Market Description, Statistics, Demographic…
-
76 Statistics
- Market Size, Demand, Demographic…
Chinese Cardiology Industry 2018-2022
-
6 Reports
- Demographic, Demand, Social Conditions…
-
29 Statistics
- Market Size, Demographic, Demand…
UK Cardiology Industry 2018-2022
-
25 Reports
- Demographic, Demand, Social Conditions…
-
394 Statistics
- Demographic, Environment, Social Conditions…
Australian Cardiology Industry 2018-2022
-
10 Reports
- Demographic, Demand, Supply…
-
123 Statistics
- Demographic, Environment, Social Conditions…
Canadian Cardiology Industry 2018-2022
-
6 Reports
- Demographic, Demand, Forecast…
-
36 Statistics
- Demographic, Environment, Social Conditions…
Asian Cardiology Industry 2018-2022
-
4 Reports
- Demand, Market Size, Forecast…
-
19 Statistics
- Demographic, Environment, Demand…
SOURCE
2012
Dr. Joseph Loscalzo of BWH, the moderator of the Cardiology Panel — NEJM Dialogue in Medicine, June 22, 2012 has asked the Panel members: What are the new innovations to be foreseen by each member of the Panel which included Panelists:
Emelia Benjamin, BMC
Eugene Braunwald, BWH,
Desmond Jordan, Columbia University Medical Center
Thomas Luscher, Professor and Chairman of Cardiology at the University Hospital Zurich and Director of CardioVascular Research at the Institute of Physiology of the University Zurich, Switzerland.
Craig Smith, Columbia University Medical Center
Dr. Craig Smith of Columbia University Medical Center bet the future of cardiovascular medical devices on the Implantable Synchronized Cardiac Assist Device which has three version, Left ventricle, Right Ventricle or both
Dr. Eugene Braunwald, Founding Chairman, TIMI Study Group (TIMI stands for ‘Thrombolysis In Myocardial Infarction’ and is the name of an Academic Research Organization (ARO) that, since it was founded by Dr. Eugene Braunwald in 1984, has conducted numerous practice-changing clinical trials in patients with cardiovascular disease or risk factors for cardiovascular disease, he has expressed anticipation of the next big and much needed to be available — the Multiple Pill, one drug that is a combination drugs of ASA, TZD, BB, ACE, Statin.
On this Scientific Web Site — Frontiers in Cardiology is one of the Research Categories on Cardiovascular disease, research directed by Dr. Aviva Lev-Ari, noted to be of great relevance to the innovations foreseen by Dr. Craig Smith and by Dr. Brounwald, as expressed by them on June 22, 2012 in Boston, MA
To read on Implantable Artificial Heart — go to
Lev-Ari, A. (2012G). Heart Remodeling by Design: Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony
To read on the only currently available Multiple Pill — go to
Lev-Ari, A. (2012b). Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
http://pharmaceuticalintelligence.com/2012/05/29/445/
To watch the video of the Cardiology Panel — go to
http://nejm200.nejm.org/news-and-events/dialogues-in-medicine/?panel=4
To review our post on the Cardiology Panel — go to
To review TIMI research results — go to
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.